Payment overview · 2025
General Payments
$423.18
16 reported records · 7 companies
Healthcare provider profile · identity verified
Guozi Weng
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · NEW YORK, NY · NPI 1124790605
Verified facts
What the public records show
CMS Open Payments records show Guozi Weng received $423.18 in general payments during 2025 across 16 reported records.
Gilead Sciences, Inc. accounted for 58.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Vemlidy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $248.45 | 58.7% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.67 | 13.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.36 | 6.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.89 | 6.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.46 | 5.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.90 | 4.9% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.45 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $423.18 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $57.67 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.39 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.89 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 122 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 232 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
232 | 51 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
191 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
122 | 121 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1559 | 403 |
| Vascepa | Icosapent Ethyl | 1290 | 325 |
| Losartan Potassium | Losartan Potassium | 1102 | 284 |
| Amlodipine Besylate | Amlodipine Besylate | 994 | 250 |
| Diclofenac Epolamine | Diclofenac Epolamine | 807 | 227 |
| Metformin Hcl | Metformin Hcl | 625 | 158 |
| Ammonium Lactate | Ammonium Lactate | 617 | 176 |
| Tamsulosin Hcl | Tamsulosin Hcl | 606 | 147 |
| Simvastatin | Simvastatin | 515 | 114 |
| Fluticasone Propionate | Fluticasone Propionate | 425 | 180 |
| Alendronate Sodium | Alendronate Sodium | 321 | 81 |
| Mometasone Furoate | Mometasone Furoate | 303 | 138 |
| Montelukast Sodium | Montelukast Sodium | 293 | 67 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 270 | 60 |
| Omeprazole | Omeprazole | 255 | 145 |
| Bepotastine Besilate | Bepotastine Besilate | 251 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 240 | 66 |
| Jardiance | Empagliflozin | 232 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 223 | 105 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 214 | 76 |
| Finasteride | Finasteride | 204 | 47 |
| Azelastine Hcl | Azelastine Hcl | 203 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 70 |
| Ibuprofen | Ibuprofen | 197 | 158 |
| Vemlidy | Tenofovir Alafenamide | 191 | 30 |
| Atenolol | Atenolol | 155 | 32 |
| Meclizine Hcl | Meclizine Hcl | 155 | 123 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 152 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 149 | 43 |
| Donepezil Hcl | Donepezil Hcl | 137 | 32 |
| Lisinopril | Lisinopril | 135 | 25 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 127 | 82 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 122 | 121 |
| Dexlansoprazole Dr | Dexlansoprazole | 117 | 35 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 116 | 63 |
| Januvia | Sitagliptin Phosphate | 110 | 27 |
| Creon | Lipase/Protease/Amylase | 109 | 30 |
| Restasis | Cyclosporine | 108 | 34 |
| Ezetimibe | Ezetimibe | 105 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 30 |
| Farxiga | Dapagliflozin Propanediol | 103 | 31 |
| Trazodone Hcl | Trazodone Hcl | 103 | 84 |
| Hydrocortisone | Hydrocortisone | 102 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 96 | 69 |
| Glipizide | Glipizide | 93 | 19 |
| Glipizide Er | Glipizide | 90 | 20 |
| Alcohol Pads | Alcohol Antiseptic Pads | 82 | 59 |
| Metformin Er Gastric | Metformin Hcl | 82 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 22 |
| Famotidine | Famotidine | 80 | 29 |
| Procto-Med Hc | Hydrocortisone | 77 | 32 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 75 | 18 |
| Metformin Hcl Er | Metformin Hcl | 74 | 20 |
| Synthroid | Levothyroxine Sodium | 74 | 20 |
| Acarbose | Acarbose | 73 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 73 | 59 |
| Rybelsus | Semaglutide | 71 | 18 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 67 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 66 | 17 |
| Azithromycin | Azithromycin | 63 | 58 |
| Fenofibrate | Fenofibrate,micronized | 63 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | 27 |
| Clobetasol Propionate | Clobetasol Propionate | 62 | 44 |
| Nexium | Esomeprazole Magnesium | 60 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 18 |
| Allopurinol | Allopurinol | 59 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 58 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 58 | 13 |
| Nexletol | Bempedoic Acid | 55 | suppressed |
| Xarelto | Rivaroxaban | 55 | 15 |
| Loperamide | Loperamide Hcl | 54 | 43 |
| Halobetasol Propionate | Halobetasol Propionate | 53 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 53 | 17 |
| Fluocinonide | Fluocinonide | 51 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 46 | 11 |
| Eliquis | Apixaban | 42 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 33 |
| Dutasteride | Dutasteride | 41 | 13 |
| Tradjenta | Linagliptin | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 12 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 38 | 18 |
| Ketoconazole | Ketoconazole | 37 | 16 |
| Ursodiol | Ursodiol | 37 | suppressed |
| Carvedilol | Carvedilol | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Gabapentin | Gabapentin | 34 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Linzess | Linaclotide | 32 | 13 |
| Mupirocin | Mupirocin | 31 | 23 |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 30 | 22 |
| Irbesartan | Irbesartan | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 24 | 12 |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Proctozone-Hc | Hydrocortisone | 23 | 14 |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 23 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Entecavir | Entecavir | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Prolia | Denosumab | 19 | 17 |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | 16 |
| Ciclopirox | Ciclopirox Olamine | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 16 |
| Glimepiride | Glimepiride | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 13 |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 14 |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Furosemide | Furosemide | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $423.18 · 16 records | Gilead Sciences, Inc. | ABRYSVO, ACCRUFER, Cologuard Collection Kit, JARDIANCE, Kerendia, LAGEVRIO, PREVNAR 20 | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error